0001104659-23-019702.txt : 20230213 0001104659-23-019702.hdr.sgml : 20230213 20230213161520 ACCESSION NUMBER: 0001104659-23-019702 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inotiv, Inc. CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23357 FILM NUMBER: 23618634 BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 FORMER COMPANY: FORMER CONFORMED NAME: BIOANALYTICAL SYSTEMS INC DATE OF NAME CHANGE: 19970918 8-K 1 tm236555d1_8k.htm FORM 8-K
0000720154 false 0000720154 2023-02-13 2023-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

Date of Report (Date of earliest event reported): February 13, 2023

 

INOTIV, INC.
(Exact name of registrant as specified in its charter)

 

Indiana   0-23357   35-1345024
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

  

2701 KENT AVENUE

WEST LAFAYETTE, indiana

  

 

47906-1382

(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (765) 463-4527

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange
on which registered
Common Shares NOTV The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

The information provided in Item 2.02 and Item 9.01, including Exhibit 99.1, of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

 

Item 2.02.Results of Operations and Financial Condition.

 

On February 13, 2023, Inotiv, Inc. issued a press release announcing financial results for the three months ended December 31, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits

 

  Exhibit
No.		   Description
       
  99.1   Inotiv, Inc. press release, issued February 13, 2023.
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  INOTIV, INC.
     
Date: February 13, 2023 By: /s/ Beth A. Taylor
    Chief Financial Officer,
    Senior Vice President—Finance

  

 

 EX-99.1 2 tm236555d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results

 

Reiterates Select Full Year Fiscal 2023 Financial Guidance

 

WEST LAFAYETTE, IN, February 13, 2023– Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022.

 

Financial Highlights

 

Q1 FY 2023 Highlights

 

·Revenue grew to $122.8 million in Q1 FY 2023 from $84.2 million during the three months ended December 31, 2021 (“Q1 FY 2022”), driven by a $8.3 million rise in Discovery and Safety Assessment (“DSA”) revenue and a $30.3 million rise in Research Models and Services (“RMS”) revenue. Growth resulted primarily from acquisitions, favorable pricing for both segments, and increased client demand in our DSA segment that produced revenue exceeding acquisition contributions.

 

·Consolidated net loss for Q1 FY 2023 was $(86.9) million, or (70.8)% of total revenue, compared to consolidated net loss of $(83.4) million, or (99.0)% of total revenue, in Q1 FY 2022. The Q1 FY 2023 consolidated net loss included a $66.4 million non-cash goodwill impairment charge related to our RMS segment.  The remaining consolidated net loss was primarily driven by the impact on revenue and gross margin from the Company’s decision to refrain from selling or delivering any of its Cambodian non-human primates (“NHPs”) held in the U.S. until the Company’s staff and external experts can reasonably determine that the NHPs in inventory from Cambodia are purpose-bred.

 

·Adjusted EBITDA decreased to $(5.5) million, or (4.5)% of total revenue, from $10.1 million, or 12.0% of total revenue, in Q1 FY 2022.

 

·Book-to-bill ratio was 1.02x for the DSA services business.

 

·DSA backlog was $147.9 million at December 31, 2022, up from $147.2 million at September 30, 2022 and $104.6 million at December 31, 2021.

 

Reiterating Select Financial Guidance for the Full Fiscal Year 2023 Ending September 30, 2023 (“FY 2023”)

 

The Company's guidance takes into account a number of factors, including existing DSA backlog, current sales pipeline, trends in cancellations and delays, trends in pricing, the impact of new products and services and recent efficiency initiatives including the announced facility consolidation plans in the U.S. In addition, the guidance presented below represents the Company’s best efforts to estimate the impact of the NHP supply disruption that was identified and disclosed in Q1 FY 2023.  For FY 2023, we are confirming guidance of at least $580 million of revenue and at least $75 million of Adjusted EBITDA with adjusted EBITDA margins of approximately 17% for the nine-month period ended September 30, 2023, as well as capital expenditures of no more than 5% of revenue during FY 2023. The select financial guidance for the full fiscal year ending September 30, 2023, includes the shipping of our existing Cambodian NHP inventory. Subsequent to January 13, 2023, and after an internal analysis and review, the Company has shipped a select number of its Cambodian NHP inventory; however, the Company is not currently shipping Cambodian NHPs at the same volumes that it was prior to the events on November 16, 2022. The Company expects to establish new procedures before it will resume Cambodian NHP imports. The Company expects that future imports of NHPs from Cambodia will be dependent on working with third parties to establish additional procedures aiming at providing additional assurances that future NHP imports from Cambodia are purpose-bred.

 

Management Commentary

Robert Leasure Jr., President and Chief Executive Officer, commented, “The investments we have made, the foundation we have created, and the improvements we are implementing have put Inotiv on a path to becoming a stronger and more efficient company. We did have some unexpected challenges during the past quarter, which we are addressing, and we continue to work to improve our business. We believe our business is well-positioned to achieve above-market revenue growth rates and a significant expansion in margins through a combination of increased organic sales growth, synergies from our acquisitions over the last 14 months, and the benefits from our ongoing site optimization initiatives. We continue to advance towards our goal of achieving long-term revenue growth rates of high-single to low-double digits, and Adjusted EBITDA margins of 18-22%. I remain grateful to Inotiv’s dedicated and hard working team of professionals.”  

 

 

 

 

Q1 FY 2023 Review

 

Revenue (in millions)  

 

    (unaudited)     (unaudited)               
Segment   Q1 FY 2023     Q1 FY 2022     Difference     % Change  
DSA1   $ 41.1     $ 32.8     $ 8.3       +25.3 %
RMS   $ 81.7     $  51.4     $ 30.3       +58.9 %
Total   $ 122.8     $ 84.2     $ 38.6       +45.8 %

 

1 includes BASi Products  

 

Higher total revenue was driven by a $8.3 million increase in DSA revenue and a $30.3 million increase in RMS revenue. The increase in the DSA revenue was primarily driven by revenue generated from Integrated Laboratory Systems, LLC (“ILS”), which was acquired on January 10, 2022. The remaining increase was primarily driven by an increase in general toxicology services. The increase in the RMS revenue was due primarily to the timing of contributions from the acquisitions of Envigo RMS Holding Corp. (“Envigo”), Robinson Services, Inc. (“RSI”) and Orient BioResource Center, Inc. (“OBRC”). Envigo was acquired on November 5, 2021, RSI was acquired on December 29, 2021, and OBRC was acquired on January 27, 2022.

  

 Gross Profit1 (in millions)  

 

   (unaudited)       (unaudited)     
Segment  Q1 FY 2023   % of
Segment
Revenue		   Q1 FY 2022  

% of

Segment

Revenue

 
DSA2  $13.1    31.9%  $12.2    37.2%
RMS  $8.6    10.5%  $7.1    13.8%
Total  $21.7    17.7%  $19.3    22.9%

 

1 excludes amortization of intangible assets

2includes BASi Products  

 

Higher total gross profit in Q1 FY 2023 was the result of a $0.9 million increase in DSA gross profit from Q1 FY 2022, and a $1.5 million increase in RMS gross profit from Q1 FY 2022. The decrease in DSA gross profit as a percent of DSA revenue was primarily due to laboratory capacity investments and costs associated with the successful recruitment of scientists in Q1 FY 2023, to begin adding services and capacity which we expect to have available in Q2 and Q3 of FY 2023. The decrease in RMS gross profit as a percent of RMS revenue was primarily due to the mix of products sold and inflationary pressure on product expenses, energy and wages, partially offset by favorable pricing for several different RMS product lines.

 

Consolidated Net Loss

 

Consolidated net loss for Q1 FY 2023 was $(86.9) million compared to consolidated net loss of $(83.4) million in Q1 FY 2022. Consolidated net loss for Q1 FY 2023 included a $66.4 million non-cash goodwill impairment charge related to our RMS segment. The Company determined that as a result of the November 16, 2022 event, which led to the Company’s decision to refrain from selling or delivering any of its Cambodian NHPs held in the U.S., the uncertainty related to the Company’s ability to import NHPs from Cambodia and decrease in the stock price, the carrying value of our goodwill as of December 31, 2022, must be quantitatively evaluated. As a result of our impairment assessment, the Company determined that the carrying amount of goodwill attributed to our RMS segment was in excess of its fair value. Additionally, in Q1 FY 2023, the Company incurred $13.3 million of depreciation and amortization expense, an increase of $7.3 million from Q1 FY 2022, and $2.0 million of stock compensation expense, a decrease of $21.9 million from Q1 FY 2022. The Company incurred $10.5 million of interest expense during Q1 FY 2023 as compared to $4.8 million in Q1 FY 2022. The remaining increase in operating expenses was driven by increases in selling costs, primarily due to increased revenue, and in general and administrative (“G&A”) expenses, reflecting various acquisitions, as well as strategic investments in unallocated corporate G&A expense to support additional revenue growth, which included additional headcount, higher compensation expense and higher legal expense, amongst other costs. Additionally, Q1 FY 2023 G&A expense included $1.3 million for legal, consulting and audit fees incurred in connection with the impact of the Company’s decision to refrain from selling or delivering Cambodian NHPs held in the U.S. Consolidated net loss for Q1 FY 2022 included one-time charges of $56.7 million of fair value remeasurement of the embedded derivative component of the convertible notes issued in September 2021 and $23.0 million of post combination stock compensation expense relating to the adoption of the Envigo Equity Plan.

 

Cash Provided by Operating and Financing Activities and Financial Condition

 

As of December 31, 2022, the Company had $20.8 million in cash and cash equivalents and a $0.0 million balance on its $15.0 million revolving credit facility. The Company’s $35 million delayed draw term loan (“DDTL”) was drawn on October 12, 2022, and a portion of the proceeds were used to repay the $15.0 million balance as of September 30, 2022, on the the Company’s revolving credit facility while the remaining was drawn to fund a portion of the Company’s capital expenditures in 2022 and those planned for 2023. Total debt, net of debt issuance costs, as of December 31, 2022, was $373.2 million. We were in compliance with our debt covenants as of December 31, 2022. Cash used by operating activities was $7.4 million for Q1 FY 2023, compared to cash used by operating activities of $1.1 million for Q1 FY 2022. For Q1 FY 2023, capital expenditures totaled $8.4 million.

 

 

 

 

Subsequent Events

 

·On January 9, 2023, the Company entered into a Third Amendment to the Credit Agreement as outlined in the Form 10-K filed on January 13, 2023.

 

Conference Call

Management will host a conference call on Monday, February 13, 2023, at 4:30 pm ET to discuss first quarter reported results for fiscal year 2023.

 

Interested parties may participate in the call by dialing:

 

·(877) 407-9753 (Domestic)

  · (201) 493-6739 (International)

 

The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:

 

https://event.choruscall.com/mediaframe/webcast.html?webcastid=7fu8sVnU

 

For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://www.inotivco.com/investors/investor-information/.

 

Non-GAAP to GAAP Reconciliation

 

This press release contains financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (GAAP), including Adjusted EBITDA and Adjusted EBITDA as a percentage of total revenue for the three months ended December 31, 2022 and 2021 and selected business segment information for those periods. Adjusted EBITDA as reported herein refers to a financial measure that excludes from consolidated net income (loss) statement of operations line items interest expense and income tax (benefit) expense, as well as non-cash charges for depreciation and amortization, stock compensation expense, acquisition and integration costs, startup costs, restructuring costs incurred in connection with the exit of our Cumberland and Dublin facilities, unrealized foreign exchange loss, loss on debt extinguishment, amortization of inventory step up, loss/gain on disposition of assets, loss on fair value remeasurement of convertible notes, goodwill impairment loss and other non-recurring third-party costs. The adjusted business segment information excludes from operating income and unallocated corporate G&A these same expenses.

  

Adjusted EBITDA and Adjusted EBITDA margin guidance for fiscal year 2023 and periods within the year are provided on a non-GAAP basis. The Company cannot reconcile this guidance to expected net income/loss or expected net income/loss margin without unreasonable effort because certain items that impact net income/loss and net income/loss margin are out of the Company's control and/or cannot be reasonably predicted at this time, which unavailable information could have a significant impact on the Company’s GAAP financial results. 

 

The Company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the Company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures as supplemental and in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

 

Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of our results and to illustrate our results giving effect to the non-GAAP adjustments. Management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

 

 

 

 

About the Company

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.

 

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

 

Company Contact Investor Relations
Inotiv, Inc. The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer Devin Sullivan
(765) 497-8381 (212) 836-9608
btaylor@inotivco.com dsullivan@equityny.com

 

 

 

 

INOTIV, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

   Three Months Ended 
   December 31, 
   2022   2021 
Service revenue  $50,048   $38,176 
Product revenue   72,706    46,035 
Total revenue  $122,754    84,211 
Costs and expenses:          
Cost of services provided (excluding amortization of intangible assets)   35,430    24,209 
Cost of products sold (excluding amortization of intangible assets)   65,639    40,677 
Selling   4,507    2,738 
General and administrative   28,969    13,252 
Amortization of intangible assets   8,781    3,396 
Other operating expense   3,639    33,580 
Goodwill impairment loss   66,367    — 
Operating loss  $(90,578)  $(33,641)
Other (expense) income:          
Interest expense   (10,450)   (4,828)
Other expense   (1,878)   (57,727)
Loss before income taxes  $(102,906)  $(96,196)
Income tax benefit   15,974    12,785 
Consolidated net loss  $(86,932)  $(83,411)
Less: Net income (loss) attributable to noncontrolling interests   391    (364)
Net loss attributable to common shareholders  $(87,323)  $(83,047)
           
Loss per common share          
Net loss attributable to common shareholders:          
Basic and diluted  $(3.41)  $(3.93)
           
Weighted-average number of common shares outstanding:          
Basic and diluted   25,603    21,124 

 

 

 

 

INOTIV, INC.

CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

 

   December 31,   September 30, 
   2022   2022 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $20,820   $18,515 
Restricted cash   —    465 
Trade receivables and contract assets, net of allowances for credit losses of $7,292 and $6,268, respectively   74,587    100,073 
Inventories, net   75,639    71,441 
Prepaid expenses and other current assets   33,922    42,483 
Assets held for sale   7,560    — 
Total current assets   212,528    232,977 
           
Property and equipment, net   187,952    186,199 
Operating lease right-of-use assets, net   34,152    32,489 
Goodwill   91,458    157,825 
Other intangible assets, net   338,456    345,886 
Other assets   6,513    7,524 
Total assets  $871,059   $962,900 
           
Liabilities, shareholders' equity and noncontrolling interest          
Current liabilities:          
Accounts payable  $28,152   $28,695 
Accrued expenses and other liabilities   28,582    35,801 
Revolving credit facility   —    15,000 
Fees invoiced in advance   60,655    68,642 
Current portion of long-term operating lease   8,475    7,982 
Current portion of long-term debt   7,553    7,979 
Liabilities held for sale   2,710    — 
Total current liabilities   136,127    164,099 
Long-term operating leases, net   26,240    24,854 
Long-term debt, less current portion, net of debt issuance costs   365,643    330,677 
Other long-term liabilities   6,073    6,477 
Deferred tax liabilities, net   57,169    77,027 
Total liabilities   591,252    603,134 
           
Shareholders’ equity and noncontrolling interest:          
Common shares, no par value:          
Authorized 74,000,000 shares at December 31, 2022 and at September 30, 2022; 25,606,636 issued and outstanding at December 31, 2022 and 25,598,289 at September 30, 2022   6,363    6,362 
Additional paid-in capital   709,856    707,787 
Accumulated deficit   (435,209)   (348,277)
Accumulated other comprehensive loss   (206)   (5,500)
Total equity attributable to common shareholders   280,804    360,372 
Noncontrolling interest   (997)   (606)
Total shareholders’ equity and noncontrolling interest   279,807    359,766 
Total liabilities and shareholders’ equity and noncontrolling interest  $871,059   $962,900 

 

 

 

 

INOTIV, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited) 

 

   Three Months Ended 
   December 31, 
   2022   2021 
Operating activities:          
Consolidated net loss  $(86,932)  $(83,411)
Adjustments to reconcile net loss to net cash used in operating activities, net of acquisitions:          
Depreciation and amortization   13,263    6,035 
Employee stock compensation expense   2,046    19,159 
Changes in deferred taxes   (20,123)   (14,281)
Provision for doubtful accounts   1,078    — 
Amortization of debt issuance costs and original issue discount   732    — 
Noncash interest and accretion expense   1,446    — 
Loss on fair value remeasurement of embedded derivative   —    56,714 
Other non-cash operating activities   1,028    1,730 
Goodwill impairment loss   66,367    — 
Loss on debt extinguishment   —    877 
Non-cash amortization of inventory fair value step-up   244    3,668 
Changes in operating assets and liabilities:          
Trade receivables and contract assets   21,999    1,517 
Inventories   (4,204)   (3,393)
Prepaid expenses and other current assets   7,810    (1,432)
Operating lease right-of-use assets and liabilities, net   266    (229)
Accounts payable   1,169    4,491 
Accrued expenses and other liabilities   (5,548)   (10,974)
Fees invoiced in advance   (7,796)   10,806 
Other asset and liabilities, net   (255)   7,580 
Net cash used in operating activities   (7,410)   (1,143)
           
Investing activities:          
Capital expenditures   (8,369)   (5,655)
Proceeds from sale of equipment   211    284 
Cash paid in acquisitions   —    (227,022)
Net cash used in investing activities   (8,158)   (232,393)
           
Financing activities:          
Payments of long-term debt   —    (37,747)
Payments of debt issuance costs   —    (7,102)
Payments on promissory notes   (952)   (167)
Payments on revolving credit facility   (15,000)   — 
Payments on senior term notes and delayed draw term loans   (688)   — 
Borrowings on construction loan   —    1,184 
Borrowings on senior term notes and delayed draw term loans   35,000    — 
Proceeds from exercise of stock options   24    47 
Proceeds from issuance of senior term notes   —    165,000 
Payments on capex line of credit   —    (1,749)
Net cash provided by financing activities   18,384    119,466 
           
Effect of exchange rate changes on cash and cash equivalents   593    — 
           
Net increase (decrease) in cash and cash equivalents   3,409    (114,070)
Less: cash, cash equivalents, and restricted cash held for sale   (1,569)   — 
Cash, cash equivalents, and restricted cash at beginning of period   18,980    156,924 
Cash, cash equivalents, and restricted cash at end of period, net of cash, cash equivalents and restricted cash held for sale  $20,820   $42,854 
           
Noncash financing activity:          
Seller financed acquisition  $—   $3,000 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $8,491   $1,351 
Income taxes paid, net  $2,268   $163 

 

 

 

 

INOTIV, INC.

RECONCILIATION OF GAAP TO NON-GAAP

SELECT BUSINESS SEGMENT INFORMATION

(In thousands)

(Unaudited)

 

   Three Months Ended 
   December 31, 
   2022   2021 
DSA          
Revenue   41,093    32,825 
Operating income   2,372    6,042 
Operating income as a % of total revenue   1.9%   7.2%
Add back:          
Depreciation and amortization   3,980    2,541 
Startup costs   1,505    957 
Total non-GAAP adjustments to operating income   5,485    4,498 
Non-GAAP operating income   7,857    9,540 
Non-GAAP operating income as a % of DSA revenue   19.1%   29.1%
Non-GAAP operating income as a % of total revenue   6.4%   11.3%
           
RMS          
Revenue   81,661    51,386 
Operating income/(loss)   (71,272)   80 
Operating income/(loss) as a % of total revenue   (58.1)%   0.0%
Add back:          
Depreciation and amortization   9,283    3,483 
Restructuring costs   266    - 
Amortization of inventory step up   244    3,668 
Other non-recurring, third party costs   671    439 
Goodwill impairment loss   66,367    - 
Total non-GAAP adjustments to operating income/(loss)   76,831    7,590 
Non-GAAP operating income   5,559    7,670 
Non-GAAP operating income as a % of RMS revenue   6.8%   14.9%
Non-GAAP operating income as a % of total revenue   4.5%   9.1%

 

 

 

 

   Three Months Ended 
   December 31, 
   2022   2021 
Unallocated Corporate G&A   (21,678)   (39,764)
Unallocated corporate G&A as a % of total revenue   (17.7)%   (47.2)%
Add back:          
Stock option expense   2,046    23,932 
Acquisition and integration costs   983    8,808 
Total non-GAAP adjustments to operating income/(loss)   3,029    32,740 
Non-GAAP operating loss   (18,649)   (7,024)
Non-GAAP operating loss as a % of total revenue   (15.2)%   (8.3)%
           
Total          
Revenue   122,754    84,211 
Operating loss   (90,578)   (33,642)
Operating loss as a % of total revenue   (73.8)%   (39.9)%
Add back:          
Depreciation and amortization   13,263    6,024 
Stock compensation expense   2,046    23,932 
Restructuring costs   266    - 
Acquisition and integration costs   983    8,808 
Amortization of inventory step up   244    3,668 
Startup costs   1,505    957 
Other non-recurring, third party costs   671    439 
Goodwill impairment loss   66,367    - 
Total non-GAAP adjustments to operating loss   85,345    43,828 
Non-GAAP operating income/(loss)   (5,233)   10,186 
Non-GAAP operating income/(loss) as a % of total revenue   (4.3)%   12.1%

  

 

 

 

INOTIV, INC.

RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS

(In thousands)

(Unaudited)

 

   Three Months Ended 
   December 31, 
   2022   2021 
GAAP Consolidated net loss  $(86,932)  $(83,411)
Adjustments (a):          
Interest expense   10,450    4,828 
Income tax benefit   (15,974)   (12,785)
Depreciation and amortization   13,263    6,024 
Stock compensation expense (1)   2,046    23,932 
Acquisition and integration costs (2)   983    8,808 
Startup costs   1,505    957 
Restructuring costs (3)   266    - 
Unrealized foreign exchange gain   1,250    320 
Loss on debt extinguishment   -    877 
Amortization of inventory step up   244    3,668 
Loss (gain) on disposition of assets   380    (249)
Loss on fair value remeasurement of convertible notes (4)   -    56,714 
Other non-recurring, third party costs   671    439 
Goodwill impairment loss (5)   66,367    - 
Adjusted EBITDA (b)  $(5,481)  $10,122 
GAAP Consolidated net loss as a percent of total revenue   (70.8)%   (99.1)%
Adjustments as a percent of total revenue   66.4%   (111.1)%
Adjusted EBITDA as a percent of total revenue   (4.5)%   12.0%

 

(a)Adjustments to certain GAAP reported measures for the three months ended December 31, 2022 and 2021 include, but are not limited to, the following:

 

(1)For the three months ended December 31, 2021, $23.0 million relates to post combination non-cash stock compensation expense relating to the adoption of the Envigo Equity Plan recognized in connection with the Envigo acquisition.

 

  (2) For the three months ended December 31, 2021, represents charges for legal services, accounting services, travel and other related activities in connection with the acquisition and integration of Plato BioPharma, Envigo and RSI. For the three months ended December 31, 2022, represent charges for legal services, accounting services and other related activities in connection with the acquisitions of Plato BioPharma, Envigo, RSI, ILS, OBRC, Histion and Protypia.

 

  (3) For the three months ended December 31, 2022, represents costs incurred in connection with the exit of our Dublin and Cumberland sites.

 

  (4) For the three months ended December 31, 2021, represents loss of $56.7 resulting from the fair value remeasurement of the embedded derivative component of the convertible notes.

 

  (5) For the three months ended December 31, 2022, represents a non-cash goodwill impairment charge of $66.4 million related to the RMS segment.

 

(b)Adjusted EBITDA - Consolidated net (loss) income before interest expense, income tax expense (benefit), depreciation and amortization, stock compensation expense, acquisition and integration costs, startup costs, restructuring costs, unrealized foreign exchange loss, loss on debt extinguishment, amortization of inventory step up, gain/loss on disposition of assets, loss on fair value remeasurement of the embedded derivative component of the convertible notes, other non-recurring third party costs and goodwill impairment loss.

 

 

 

 EX-101.SCH 3 basi-20230213.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 basi-20230213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 basi-20230213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2023
Entity File Number 0-23357
Entity Registrant Name INOTIV, INC.
Entity Central Index Key 0000720154
Entity Tax Identification Number 35-1345024
Entity Incorporation, State or Country Code IN
Entity Address, Address Line One 2701 KENT AVENUE
Entity Address, City or Town WEST LAFAYETTE
Entity Address, State or Province IN
Entity Address, Postal Zip Code 47906-1382
City Area Code 765
Local Phone Number 463-4527
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol NOTV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm236555d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000720154 2023-02-13 2023-02-13 iso4217:USD shares iso4217:USD shares 0000720154 false 8-K 2023-02-13 INOTIV, INC. IN 0-23357 35-1345024 2701 KENT AVENUE WEST LAFAYETTE IN 47906-1382 765 463-4527 false false false false Common Shares NOTV NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://basinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm236555d1_8k.htm basi-20230213.xsd basi-20230213_lab.xml basi-20230213_pre.xml tm236555d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm236555d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm236555d1_8k.htm" ] }, "labelLink": { "local": [ "basi-20230213_lab.xml" ] }, "presentationLink": { "local": [ "basi-20230213_pre.xml" ] }, "schema": { "local": [ "basi-20230213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "basi", "nsuri": "http://basinc.com/20230213", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm236555d1_8k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://basinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm236555d1_8k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://basinc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-019702-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-019702-xbrl.zip M4$L#!!0 ( .F!358TSU'*-P, .\+ 1 8F%S:2TR,#(S,#(Q,RYX M?E@/2JV"K9473]@--#:;;)-LH?YZ MD]T-4%A6H,I3,G/OG9ED)DOS:!)3\("%))RUG,#U'8!9R"/"1BWGJ@>/>Z?M MM@..WKUZ"?2O^1I"<$XPC1K@C(>PS8;\$'Q&,6Z #YAA@107A^ :T=18^#FA M6(!3'B<4*ZP=>:0&V'.#?00@7$/W&K.(BZMN>ZI[JU0B&YXW'H]=QA_0F(L[ MZ88\7D^PIY!*Y53-G_C%;SWZ!9'AE+R#CO?&^Y,NN1EA]C;MH'H__(X^79+! M9?2[W]V)?]Q-5'RR,^C3^[/'KTQ$^*37Z_OHUW[\_GKW8QZR*<-;'".@+X/) MEF/J*\H;UUTN1E[-]P/OYJ+3RW!.#FQ,*&%W9?#@X.# R[P6NH2<# 2UTG7/ MN =(XJFR]I(*/&%2(18^P4=J2I@'[WFY\PF4E$+?Y%!BH1%>P$D"^UT+324<(91,X4,D!YELX-,U5-P2G^)O.&IB%'JTR9>/R3KE^'!Q MHI:3+XV&5LQ4(CPDC&2AB@D* #3SDIJB]#*C-+U%\)Q$*G%TR=YEZT1@J7E9 M[AUM*(@%9 4I1#1,Z6:<62JEE,)@SVAV:G9*NG@(LNEJF)MO.9*8]\TI;+<" M#UN..4AH+^>G+LW5/6$A1KIBNK*37SR-(K"50")<4EF:?BW"$RP4T>TY-^)Y MZD09^I>Y,,#$D0[P_D7)% TV+5E3,/V/M7:,_GR1Q7AXL_DH]HLSU-3ED4\FMD5"3RX[4L(S0D;: M-SJUBJ3^QLSV8I=I,=Q\8WL_B=7^]2+"N_$//I?T9S ME/]SV#:1U:W1]')-O?P#4$L#!!0 ( .F!35;W_8)W_PH &R' 5 M8F%S:2TR,#(S,#(Q,U]L86(N>&ULS9U?4^NX&<;O.]/OH$UOVID30J#=#NQA M=S@YL)-9%BCAG&V[T]E1;!$\*!(K.Y!\^TJVY=BR7MO0J20N(%C/*S^R?I'D M/Y(__K!=4_1"1)IP=C::'AR.$&$1CQ.V.AM]68S/%[/Y?(32#+,84\[(V8CQ MT0_?__$/2/Y\_&8\1I<)H?$I^LRC\9P]\._0-5Z34_0C843@C(OOT%=,-VH+ MOTPH$6C&U\^49$0F%#L^17\[F/X=H_%X0+Y?"8NY^'(WK_)]S++G]'0R>7U] M/6#\!;]R\90>1'P]+,-%AK--6N5VN#TL?XKPCS1A3Z?JUQ*G!,GCQ=+3;9J< MC=1^R]V^'A]PL9H<'1Y.)__\^6H1/9(U'B=,';>(C'24RL46-STY.9GDJ5K: M4FZ7@NI]'$^TG2IGF9ITZ&M.TN0TS>U=\0AG>;7W[@:!"O7?6,O&:M-X>C0^ MGAYLTWBD#WY^! 6GY(X\H+R8I]GN6:*4)HJ$4;GM49 'NQDJQ$3%3QA9X8S$ M:D.W'E:J-5_)3PR+99K(#([$VJ;+H:('S/>0=0YEWE3N/&OE2U9IST2Z[ZAGS M/%,2':SXRR0FB\*&I=+2F4J&&582-ORQ&W^<:]*M6_>?C9)^+H\J60Z'- MFK#L7N9J*44SV555VTSIFJZG!5'1%D-F/6L)4AH/E7PN=QXK Y<4KRQ%,-)= M5;/5EJ[G1F(0%6US9-9TI4%*Y+.J/Y,T$LFS&MYWE:4A6SAG;8'I'GKGH0J@IA1858H]4_&,CS^:)H+M> M,%I*UVP 5DT\#%E0A-B]@9!4V!W.01J P)"YV+%S5J MET.G@06NZ7T"U++=Q5 E#A8CT^% DO(PI.(\TE2[9='#44OIFB# JLF.(0N* M&KLWD)="CG)]&*!J-B)ELI@>F2R!31Z2XOGR'E) O5M@>FPWN0'$ >'3[1"@2 :A9I1OF.8L MXN*9UQZ7F/&-; QW,Q[#(Y:>*+=@#2I"$Z_.D( @&^(30*T1^J%XI@5Q-3 RL6K>$==AM!@-R;U YBVDF-HP\/';K"/H6J0K.-\@U0.UGN_+%KFI[5IFK0W-84F M/%":QGH;F4+M&XM;GF:8_CMY[CQ)MXN](&(U; 6EH0P/%YN]/FB*&"2#?)UT ME]BJ&R#6Z6I&NKLIQQ9;^RG'M<0@0+ Y:D\Y+JZN%"(?5:U8%00#+4,SV5E% M6TQ5]5Q+"Z.:VX9:M9Q_OZ7&UQ=:K2Q#;Q\Y@Q\N:$MXF1Y$K0.F MS)K/92C7>;QRKU:X2.U->2W-64]OVJDZ=IT01 V;;EK=MD[W4*._B"23>Y_Q M]7K#RCM#MF<0 9VKFNZTJ6O=*@J"@"YG)@VE%C7%'M!8<)I$29:PU<_RY%0D MV%8RF\@5%+!!341;$00.H"V3A;T0::4'$&X%43 261GYA$.UR)&X>7BP]OY= M8E=@]!O6@,#*($#IM6<"(P/&42T"%2$HC_&/SCQ--T2\"2!+B">,0/, 3"U] MB$A!)GO!*@)]\[4@T4;VE[OIT?(^R:CMQ+,M<=8_ >:JWLE(#X(/P)3)0YZ& M^ .:'OUY^1>DHSP@<,WO!5:+VBYVZR6GP$I85I4K$#HL:A8LDB!P@'V91%QS M5$I1H?6U4E;#L*5(1KHK"*RV=/4W$H.H>)NC5B/0J&^/S?_%-GJ4Q@@PV<$N M<]T-V$R:74%=$P0&'<9:)RNE%&FMK\D.^RYLU3\H6'D;%*QZ!@6K$ <%JZ&# M@I7708'>=;%,B6RC;I8T66%@T<1.M6LP.BR;C%BD0>$"^P/;CBH$[6-\K+:9 M+[NF7B4@UKF'2_G!4E) YVR]S2Z;U8*;-E$0G'0Y:RVY62R$5Q,CI?;!QB9. M,A(7ABX3AEF48%HMW6B[>MX?XHR8@>8K>'KT87 TS&0+J2),K[%8!>Z7X?1Q MV;UXB.,70NE/C+^R!<$I9R0NKK?8[BYUZ]T^==-CN_G@#2 . JDA#H'';U30 M^$E%(1U67BWS1M-73C=!J%YX^6:(_OQ,?3YX;*_>(U+8OM]6LJ24"(V'QUK&(CD-9ZXV&QQI1^VJ0)(RG<*1DJMSQ8 M+39Y:$@"XL'F"^ AER*M]<;#Q9J(E>SN?A3\-7LLUY %RP>HW?+1:;G)B54: M$"]=_@!N= @J8O2RO_X VNX70"]6@(1+:Y$Z1@ M<\TS=,_1EY2@[)&@B_*U>O65ZXM\?+XE)8K4A(MBM,YB+&P8=8F=OS$%--QZ M;TI+&01,O?;@=ZA4$4B'>"#G1K(LZN=XN9%Y1M;@3(K^$%<4#36O6>K3!T'4 M0),F5WE8\\0[#T0JTO>J2O4%^>%A7T/D>+1L,6@,EFN*(#@!;4%#Y?K[#?RM MY[=9TB2ZI!S#5V$:&L>K^+7M&0OX[04!4=!V!2W;EPM1KO3&P"?,GL3F.8MV MMX)'A*BGM=*JY>J[1CYLZ>.,X\!L:[/Z@87QSS) MZPT, L2WNH5. 5-4SP MU7-F91;H5Y4)RG.QO:>]ONE*?I*;]2;Y:XE3(K?\ M%U!+ P04 " #I@4U6476S[%$' "]6 %0 &)A],1M@!- M9(F5Y #_?B4;4SXL^>2F)[E("+SZ>)]C9!]+\L7;=.'#).5320Z9)30^T'1[IZ===I_?[P=QPN:DB83 MCEM,&V4I5TM5N<[Y^7D[_[24GBC74\7+-GKMLCN[FNVG+*#?ZXEF?9UW[U;& MQ.1AKVTF\BKZOC=ZN55N0B=B% MJ^T^:@^D/1QM/_-""T5GEPTGL75W>V?=3L_5_.N!R&R6]K#4S!U5C:A]T.I2 M44V%R8W>VC<.BM"UL0<3362T/))SQIK&K;E\:B>46=;=SG^OW,MF\3*G8/_]EC=V-=5&D=B4 MM7$RI3QOXYO5'$G:/ZAG)9&)K;6Z8X>*XW[MA^Y*Q9%4"566>5D74?%!P$X/ MSJVBO23*5M2,%XSO8CU3,O41VM*0GH[NP[)-_#BB5[8/B>O'D)-Y-=(C"9!I M!P-JI1M,JN^HCA5;.C8U< ^40,9=5,85WA!0E]^C!SIGKL^N.^[T2]V;X3'" M4P0(OXZE*H&_J$2R/P5)O,J;XBH_\J(,E3Q#83VB1@( M_#=,X!Z'B,PGB@C-'",(]%,UD/KOJ!U5>B#ZUYCH M_3Y?"/R;)W?>MZ<;./^](L 0_/%20G#B%C$*]U0QF=A3O0+P/Q$#R9]CDO-&KH7U/AY%7R*'847+36IOHZ/^A1('! M[XFAV%'2U1J+"- 'F5(''0J.,'XU%#M*HEIG$H'[C3#,;-Q\P:14"P6.DH&&#:(1GY#U*+'.V(P5$XOUX+U% MH/Q1TD^07;0PC$0LU5+NW6X>R,Q^-S<#F02'^)J"T)"@Y*7/L(X6F*LDLE'#S7A!>$@,T7A+[[//1=.'J4?+76Y@M"WWL>^AX1/2D#Q(Z:R8;/8 M,=B>_"%'?:F$,D=,:ZO-8;.^E]H0_B];UEUE5NNAW!$3W)!1C!N31?S=30[? MZJ"LD7) M.'VF, 9BMXQ9>X>!O8_!J^50AMEC&P@HORIF;"\&,DTSL;VOXYEA\TBAB%'2 MQ* ]!-QCR5G,#!/SC_8*4C'"JUE7Z:"@49)"OS$$RO>*NHA3>VF>KQES>Q[4 MW6SF&XE#>BAUE)RPWB@^_9'6&57/C4%%*6@D4-)#J&F,,8?&F1T&-YWN=.)V M\7A&G!,5E#=*:N@SA<#WDYPHXO8/CC?I5'+_5I5*(90R2B(8L(8 ^J OU8B/ M)%"X*!E@I1W$\>%F'2^(F%/_RHAJ)10R2D88,H5@,)'G)0,FT5<"V>HZS=[HN^((=M>AF+@*P&- >($9=@L MZAI^-; GH[D,S\4?":'$$9?@5EI# SU.">?7F6:"ZN XR_VY@7I5ZC!3U1 1.\U MB?G(D#AV"S6*,[Q(B/*0#^FA[%$W?OJ-(M"_,PNJ]J^M\@Z-;'X76E!17PH: M"92T%FH:[WR[]_2!X.GV0 =ECIC 5AG#V\>533F+AUR2X'7[@0S*&#%;K;"% MAOB:B$>5+4V\N5# WF0*,(UX=Z>\;T&ARO7F@,ZK<$H@)79MKV]AC M^&()4!P:(]0G(X$Q5(3JHGWBZ]:^X9[#6WSB?KEGS=IW_@=02P,$% @ MZ8%-5K+1K=HT$@ 7F@ !$ !T;3(S-C4U-60Q7SAK+FAT;>T=:W/:NO)[ M9O(?=#ESSDWGA)=Y!$C"G81'2T(@!9*T_9*1;8&5&)M8)D!__5W)-MA@$D*! MM)WVG)9@K797JWUI)3DG_QOW=?1,+$9-XS22C"4BB!B*J5*C=QH9VMUH+O*_ MXO[>B68#', :[#2BV?:@$(^/1J/8*!4SK5X\F<_GXV,.$W& "N-0."F12,:_ M7-7;BD;Z.$H-9F-#(=-..C4>E^/GK5-0V=)I )0_\8BDX@NHH56==? #9^-. M8P#4#@7-.*"V!TJ9F9:21R_QX4!,.XR7P28YSS!"\N6\59^!V^'P,]"X;6&# M=4VKCVV80XXI$TU(42GK0Q)E1 D@@N^QGOG\*IY<-)7T\"Q,3G"DO%G&;"IQ ME;0L*U)./]NH^CF=6"6O4@ 'H;@!AG-!,._&$I,,?L<,@7 MJ8@P-X)5^$3\SXE-;9T43^+.)[3VB8T1QQ E3T/Z?!HIF89-##O:F0Q _HKS M[31BD[$==ZPRSOO%7;0G_XE&494272V@-K&/40/W20&-U?$QJI7%#_<)Z>S^ MIOVW5/YX=G8-'WP@*!I=M7?J_)Z/[7XVP'MO@&_ DBY/>ZW3/9._)Z!MP#W\ M7S% ?I,2",;">LU0R?B23.X3\.>(ZWIZ7;QG?6*H\->NZKAWW\4Z(V] E3T' M*9?OD_>NHW!PPJ.WX)#NVQJV"+N7[H5?=) P\>PM>,JOGTK90,>3 M C),@XA&.BYP?246-P3QC:HJ,819\*\ V!CV 9?B:/S8;G$_4K7,/M<5[@23 M*=N<_1Q!!HP:2!%:"-6&2'&F#B?Q (G-4 WH2J0HE"644#PP7$X7O""Q(#03 MYD!P=UM@(HX" T@$QX(F/"FWN:AG+K$Q4R-NLPWNX33":'^@$\,J/KBD#W7Y74C0MK3I]/G5.4M74HL)(9"0H-4J789G)GY MSC-R\5!Z+K4!R-=4%[F 3,&RR]@FQ=D0/$RSMH5N,)5+.GDM\VP%&/ >NB(- MRGEH4$?(8'8+TNP3S(86*;KV60 8#YG7%"3!L2W![QC[4A*N$ 30VC1F3F6! M#C@ F,9%V?*^PB"P;5J^YK?+8)[',*P^HF5BF'UJO$;V=;G,TPU#[+4'I+ @ M4-="??;HN ?/-Y[$H3]\\O].!F_UP\>HCZT>-0J(@R:.$5?&*-9I#QXI8$C$ MBA3_^2N931R?Q >"C#^8M(8ZB5[CGHAY?G_N8(W:YJ# L;I?9=.VS;YX,J*J MK7$.$W]' CUETX*!.3W/=:P\(@DX8Z9.U6/D-GIXG/;DK)T/.\KH=PAN\'3& M.1>1^Z^/^WB _=T)<#M$;AJU3J6,VIVS3J6]95KM2NFF5>O4*FUTUBBCRI?2 MI[/&QPHJ-:^N:NUVK=G8,@-WF&FP2+5-Z%R.E6)(2F32^9W(>2=$JLW6%3IA M VP('\H3M'PB+?+.:+1L*D.>1O!\_UZ9ILBS9/E[KRY;P[MA9G(A@W7]:-[B MIQGLRGTAOF=4>#YXD8 M'T&+#$S+1@?>=X(AR!)F(_(,D,@2S43]4 !.YJQ.FK.Z:Y'&59PD+]S\DJD\ MR8R^U1X^I=8V/Z<63R-\%,+4*IAG)'BBX2A-<"CIUQ?!\[J6<'7-69^V M2(\R7IBS^7H]7-6D4D?MYP5E;U"O4&PXJ8PS>C(^5.P!K.D:$&6(#HO"UI(HH3(?-$/@_\ ?6A_!Q MQ85F%W<5%WYU.TI)H6:T]E3.6TTR8#4U0S$M<.>BD-VVP1>6G))MR527&%&_ M7*I??DOD1CUE$_Z:U]MYZ< F \M\YAH7=-@K\ E&9Z@4&W@%>UN8%E?LTM\S M30H#^TEF+Q^8O2K5"8Q5)E;X5%TWRZ,O)(/'!MZ8OYO1C!0342F5RAS]_F(O M!<3>P>.:6U!3A$*^- ?ZQ;-&[QYR+'&TL3E8PD"DF,H ?#J3D!9JLEL./>M' M&F',/,$V(;&VT /DU4RE3N9M=D]DRRF^4K\#^!"J6B\JTB99+IG]/F5\&QAQ M:T".]-^9J5JKC2K]@6Y.0(I![4 -,[;UX.S9\6\6CM/YOZ>=MY._S/N:HX"O M.5-5BS#F?M2I09)+PG+&N'TX^D*J^<>-^9D0XI&B=)1(HDN^[#^[K31N*B^N ME'8HMUR8W$KP8]/JF",C7&HC4^I\RR<^9U+=34MM1CI2O*NT.ZA^5CW[6NET MEDGL<*&&)84-23C,IG4-V1(XQ25)VG7]D5FYCY4^R40"WF9Z=*& AH,!L11^ M#&%G:5SX$")%^DK^-MA)%K%]6_<[QQV:1BI,CZY-F"[]&QTL3_6[GQ\SYW(I M4WO*Z:-\(@OP.>DU'?@YLA9W%'QQ/+! A^D ZXB,B3*TZ3-?,T/L M)>R=4P*0+N+BW5GLWW)]WHJ4Z?;TA^ US/TP1+S::BZ8RT?-'W:]2\'X8,$N1)I%C2" 0# M7M3' PA=8,U\/2*;8R03W1PAZE3\JQ#J4"YZB;I4YRI&&>B;30R5J/M[MHD8 M[0]U&QO$'#)]@A@DWJP[$5W='J8,E+&[KA$-OK+:$!!9"!L3KZUKZD"=]^/Q ME/+%!BML6Q9+WUSJ(V: A?+0X-=RG&PHVVW!YW/H\_IQ_89O9 M9-/4"3;$H2F_.8>RY,Q[[GB5DD%XH)K*?SM('J%2M85 J#$ G N^(NYMK1C]QX0V:D)9UX3:D)\K,,-&[PJ\ M,KAF/=Q^U/&7;$HR2HGG]3=V5K&?17[>WWAF/.WO]5VN%BTGF<;1I.0SGL"V M]=1TTHF8 _G'>GY=Z_$V1J\MPCT]/ZPJ3J3P;,5J=KO+4L?&I4;O4L:UE5:W M:D7+^7I_:P+>HHJ/N==C4C*M1J4#^<-JMN7 _K&N7]>ZJN'656-L2*Q7;2R; MP]*P?YTFW]9?5*YA8PO<_9*6EB+1](&RFJ6YL%NVM"6['FNC=M9->#)W#0HR+F(25"KQ $L.#K.;QQ& MBAU^FXE$(KW[J^I1)4I*% M?H:'.[/\]7OCYA.];6?@YEBY+*N))R%=W1\W Q ME>1/ZDU?:^72T@;$%" 8*3::G=N?3#2Y.27RPOCRHYNC)R5_U%?.7&G,HPG\%80#QN8J?@)M6U3>417V'HD-JK72TMDBW9['')9EK\E*OS$ MG2(JY1.DB!(Z]'H$YT;$,9ZY\C9E".8?TCR.N(=ZECFR-9'P#7C-&S.DDBXX M2'&DU*GT)3*+A^U]1^Q3Z( /].A85/L\8"H.HP[X851^I,C)&B4Y*H7@\N9W M?\]W<'^*E:>0LXX^O+%?98?#HCTM+&5<+1I&BI4EL^4Q[2CW4NPOK* R@>UH MC\Y'0:;D$%FR'WT#8%JJKG6S6UT\O<#8JNNF;4[I;BQ\;<6I=??W%JT=N>K# M]VE#70==V!33P"\0'58FX!<,4ZQ3AHP(*&!8[+TA<9Z%BK6+:8,.H*[P8;":Z58$:^IX*SR%Z&HV%*9L^NF+ELEI0[P M=)7D7X+&WFX[?*K[TA/Z.57W^78G^SRZZ+L?CL-X-([!B1/ M0U[Q 5J.*$72N3BK2V\M^_4E*8442K)BY;;&P,(NU*Q6E1%GDYR;Y0O#L0A^ MC,H$O!*,>2!DX$>:#4'*A^4?@D_B_@D,D/0KZR[T=#=ZQ+-N:DS?M#3SRI F MUFS21U(L(8%W5\6W_;U\+)'T'P2JC#4J4QOE\S%X[J5RT[,<\+-,.%QW:!F4 M:8"8XV(:UG41<60"B2D$,A7]\UL@S7]QW(MD![_#/7SE)2AS[@<6CY/&'P^DA^1$$,,2&\@,0Y&&) M=]0IEJGND!+$L;V_Q]QXM3"HV6EZ( QA>/I2$WZHQ13ATHO# H$XV,F+M+.# M^JI[D1()H2S?E3VU*0!H@9P7R!_<0CQNF-[<&^+-3$VQ+KKA-,U^FFSJ#V$(=[:V[ M%_.H6X0-=5M857- +'=S@IM4U4LA]_=*)B2UO&6!_GOM[FV%BOL0,GC"D29B M&3Z730,MW)\^1#7P-?3Y<'^O9B@Q<+5LR-TK$J8')@8++_!BV## [!7A@Z<) MN>5*W/.QMF81@L2=;E@0"&=9)@KAYQ%1*BGH23'$8T5W"#Y.O'7)=< !:OM[ MX/!]KIX%XH/C2?WA@<^Q..?GG.EBO^9'ES#C+VXE?$^X_"VYUX>2IDPQ:(#GCS\ MV.W<4-[7>[C^)1M7K[*OW,ARP7+CQR3\6&?^R:F,=4^N]E98T?8M5-B)#(AP*)R:&7'BVD4;'YL6U*+5YF-9E( MKWYUZ15<)1/X$]4?IW.-5U:P(NY)E;&-G3O4!SR=4WEJQPNVD&'Q[*TF7KF, M^#N7I^O-#[%M[ZOMO$BVPU1]E<* M@\;IR 0QX P:3.>%2#+1L-[EBT2.2)3&7 !>N2)#PS;W]P1"/+0UTP)OJ>YD M%?DS'L9;(5IQ9-SGGT:D5X-LX/5;FWC9B3O,S(K9PXI@Z;D,:8VX_DI:"4O6 MPF)"$1[67T9U/BF\F%V_G!>_-F-Q%D?GQ-;060QU\$0WK9VEP:\D+AHEW5F1 M#S7%I6[K\"=AKTT,:EKH%GA"UY!-BG=\\\V"I'3L,$W>Z9TO[Y'/_/A05DF- M4L>H*59JK(#JF-D_3Z:TM;3%)Y@X_^4%HOK!?U%&<<5?E9 [OQ>G-<059M^O M6" 7X^J#6KD1\+SXN9^MUL_E)KJ4^M2U:/=?+W5)BV#:J5DM_,KJ# MBSB6%4U[/*\=/4B9S^;WBF;C[&=3_G[%_NV-ZD\#O7)=RWU]NLJ8=?)XETF5 MNO1;.I&4Q[FG=/=9.K_\\OCQNG,E?\_WAYFA,XMKGIW/EVY.=SR=ZQC?\4+N8 M?*JD)^?_UCYKQGGOUDI>U#/RI'YQ^5I(O617ET>NJ(Y/]02P,$% @ Z8%-5K<6H+#+/ ;>X" !4 M !T;3(S-C4U-60Q7V5X.3DM,2YH=&WM?6M7V\C2[G?6XC_TFY/,ZZS3.)9\ M3[(Y+[=D.(< &\CLM3_*4AMKCRQY=($PO_Y4=>MF2\9&MG%;:-;* +;4E^KJ MZKKU4U]_O_MQ<;B_]_7WLZ-3^$GPOZ]WYW<79X=?/XF?\.VG\.NOQU>G_R:W M=_^^./O'NZ%C^Y^)TICXY,X<,X]V/- MO3?M ]^9?":-+R3\<^#XOC-.?V*Q(;3?,.TOQ&>__ /3-I@]]8EFF??V9^*: M]R/_W>'7X\.S7R-S8/JDWZ\K7S\=PQ2N9SI?=M#1** [>+0QW>%_ L\WAT_O M#G^S!][DRX9ZT6&VS.7S.K<=WWR@Y-S6Z^3(MIW UJ'5;Z;K^>2?@>;"@_"7 MIVO6_I[:4)OPAZW9NJE9Y(9Y@>5[&R1'--#7HL8-,^%7S8>6;IG%=)]\"RR+ M_)MI$1'(- WV][X'I@&_LUVG0LQY0(9_G=W>D8NC;T?_/KN[.P/FN*3D&QNX MP Y/1&E23@2<\&^VH7FC+[A]ISFI=JEYAO;79W)Y=??'1U+S1XS\9AE_!RGWUS^%XT^_A>;_>0J<,./B.-&'XI>PL\_4H*CT(C%-,.T[_?W=""% MJ\&ZN&+#FS@.#6>.W!GM@EC,9PW(0C[D/)NX4_"+N;.P8S/+V]\2'%C"2 M02:N8P2Z+YZ,7J/$=PP-FQ4[SB##>%NY8EN1(:/7,:@:=L?>:06TN&? M"OGV;[X.$2T( REFD%.FL_$ -FU3H7S'JO6=EE5IOOSZ\S"1/K^#;+90/H, M^GFX\S(Y/<]D<:=F^>HSO#LZOC@C)V<7%]='IZ?GE]__\:[QCO]]>WUT$OU= M<"3/'-./IN&/L*W&!Z#'W4W4!>Q$OCFC<4,+IX#H38VK:?/Y/9I/'"L+X1_Z)E_,S%[H.+8- S' M!SKBNYDN\U<]TTVZQ1N0/'; R+T+-/4=\EZ!;=TC, X+Q-K^'HBR%,\,76=, MWO=:=35Z@AB!BR(O(TZR,@.;4+)B1DU$KN&:,!HR .D%O=2;R3!'L72RPVGR,4P>=]L) V3J-V;2,[^X')6M!X) MXJC1FQ^W4:,P(M%JG7QWG4=_%,I6+I5-X#M81T$M3?\K,#T3#PG@TZ'VX+C: MP&+XF(Z$0UD,##H" 7Z/4X"'L'/3UEVF>= >'",X,X.-Q>?$"5P"\XM>V-_S M1YH?'@;,B*?+?NF,X=F5'@+AQY@Y"/AXZFD^0I7Y[@9_Q[UYN 914.UZ67?] M"2R^8X%ZB0QK,Y]8CB?4 KXM0WW\4?/(^UJO4^]_C#8,186IUFW4>Q\_$&<( M%/.Y7L%9C@)W@0;F0IL@2?3Z=1;\7X'M>Q !\62W#N.\0@?$A-&;+I<>.@CX!P6JU" -=-C1\"H,TF5#%P:QO\>?]AC,%,8#1 5)!OUQ\0SO(FU- M4/Y.-& SP]0$,48!;"@Q1#\EZBY_O_9B 3IB%A<\.)"?]=LZ"6S?M'+'Y?G: M<"BT5.!*YH+6"[],8)]Y1-=PIIKGV" @1@,OA^;-IX;(+^P->P5.S)MH(?O MN*$(C49,@+7()' GCL<.!L!FE?QZH_+KR, '8:.='9_?G1[A=@A/2U1A:NUZ M&T[H*?G2@H_R));0:)1&79F21XI:;^0]/BV,*O9[F^QW[#A_ KT.!GB N.@ MX()>J3?47WB*HDK&0ATMU"$'@0>BSJM4KK?*,\@- TW_TW+NA6*EM+KU?F+A MP!$X:RRIE 232$+!TXG1!0_?LHD?/MT03W/U 419J]Y)/Y@QP5Z;!3?JM8G\ MJJCD1([5V)$3>5"3/N1)Y9AOB_1F2-F-]:,8CMFV_4,[#@HD+ MK===HLC]MT?N(Z+YVI\,U3$X4C5==T#I W7:#I! ^WMP- Y!>W5K('!=[MG4+&AP8DY +[7A,/7A4X,K?#IV:%GJ%'E%+>_+2 MSX0&,TWISGP8-LPRUQ,:.E#1QTW8< AO,UM_@J; $H:>'IB7&CDVFG*9:KII MF?Y32JO'W32Q--N;TH3/88L9!C>MJ>"PF'P3]-W:J*0,F.4\PDC"3[Q&5>R8=I#$Y7S^V0^T#ET8(&:Y9/W[5XC MEC'PQ92+)7QH?^]]MYU^:%9I>S3]$5!O^D/!FMQ.U":PK+\X$6"F2O=#[+<& M@XL=<#\3 =/"=(S0VY3=P+ H(&L?@;>(AA;(Q/1#BP2VO!_ @F!/MD/&CLL- M$9NT/Z1G%+JW8IKA7O&$G$G\ZOFR=BHNW#!%MX M(W,RX?;;D%N?\8Y*S#9<_MA"JI/;8."QOP+D$#",Z-=\F"R1YIF3#("@O'1<#,ZG+/8_EE303ZN=,-0E^V MXT?2P'K:WXLG.]601T)ST-/&C#PX5C#FQ(%/33^RJ)'0#G\*%PK& CQVZ3P( MVBH=FO(61/WCJNOQY@(;U/1&*#WV]X#/8-=S;ABP(7("=L25.^9![[,3'4]P ME\YI'<17'Q>T]8L[V +,:0&[DG#R;QZ+A_(DGX[O!'IFN0B08Z M$YL9>"1V8"E3P]=,OFF%/_#!%.Z_Y$G-\P)7XW'8]#A3D^)CW-][SN1>TY'W MNGK"#^#W>\;=/+!B^!-VR6L=XS<.<*5/+D L(KG_KUNGY!J6BPMJO@%/1B8; MDK-?3 _P9-K?N\(#"W>0+D;+C#AZB5R'>\WSN;\89?9(>V P$H.)'3>$8RP\ MLJ(OT3[FC6!OX9'BXGZ)FM $OUK\$V0;? VV1N 3$1G%':8!+R);.L"W,##. M7<3S7<>^Y_+%$'(T.FU]X1"T04K]"_C<-,18/ >V5&"+'8,>[I%F60R:\-+1 MA D>-'^)/ $0XX\C4Q]% P66!O)Y7!W 7A_YD07#!HD-@\,]A#_#.7)!&AM@ M.!0XD4TV\P7*)SPH#H#7^7X1W@1-'_%'M0&T= "K_2?S8^\_>NNX\Y\[ST2 MP8.UA\,75!H?A0)H#+@.-=< E0.;NG= PN"YS2F&C5K0^@%Z^4@N MO>#9D7D_.L!UM'B[H"<=&$Z \1'#O#>C8,BLYI!2$I3>@:I^ $6,"%?L_MX] M-@X',+87Q?1CKZD!Z^*'>M$(AAZ+6Y]I8VP/&&:(G(7BTJM'60)?CV-A59I@ M<-3^?QT<@$7$+.,SN081^04:06U"1\N5'!R$"59?3\__R$N&4M2)G['_._C9 MP'$-YL:?'5M@#A %1L05:AC 3'(5'VYZ]E\_09\YW<,QI/UY( [JSR F<,SI M(75R1H3#?&F7*<)\0LH(8NS\NO/C,!5!N>&ZW[8MVL)*!,^M$L*%C__\L(:R M5I@='ECJYX=D[9VNXF0+]X7N@+T[\8"#H]^FG&;+F_/O.+\^XV(3>^!=Q-9W MI_'P[TZ3#Z.W)Z@N@MB.=TYZATR]<'*%T[O\QSOU79Y?(DY^>]8MANL5V!H8 MX2"6^6I->Z<*CTZ6Z41]23VI]70FX^BX=_.E&V1FJT9M#S)'V/.\<'QX*^+& M0K"NA0-R2/;\*.=DI"X:>7) K''P\L]6?0NS/36'0^:R.+6XW+/] ,:U!L;E MRG-=7I1\X;YOL'7 #,>#WG$_D_]UDW,^-E'BLTH_^MMI>?T_--?9@*-*\D:!Y'H'OFB)E<\;8@.?C'[7I/ MA]44JN>9\R6'QW(,J]2[VSHO?]R@KR:>)VOQ\V.2ZVW%X_L#O,+7S3=L-D7+XI:5^%%(MSK&]@$4^T7 M6'A^\63=E'@KQ,,K.17MBM&NV:MW=H1VJ[U?1!JWVL4V92%Y+'$2(G?M"N.; M".L[3MLY/KHUR768@;:)>,-6DP/QFBA&E=-Y\#P)9]YEO3B,S>_KW1Y%+XE; M(;,7\-(/XTV;^%J=R')(OHPRJM-#R+M9$T>:F;3(D4LL1P!2W44YD;Y(AW(&4[?^TON M%:73!W@VY9G]8-X[O/7?'8OG#YTX[J0>$T<\D-#GQAF8M@5.SR^/ [ MOVD&@FMHB@A%RK5(JCCJ\F&B[.V!E--X[F/1K0/_R8)/,"_5U)=WE2_16+Z_ M?"H\N=H ER3!R^:Q( !8D5UJLJ\2;/)]T&'9Z2CG#S=QCRAG&RW;)#E"(9^M_/4:VBQ8?_B!A3E!%M05\ MI;X"A993#5:FTW+=%*'6YF#!!/>&>7=D<_U,):)LM*=XXXF>EF:OY52TM87C MW?M!36VTJ-KL4;7=_OAL7#[G@NAR@7HU&ZC/"]'G74!=)K:9LS&SMU_?S^E6 M:2QZ/_00*4T,S^>WL=P0\D7#_#;6.?WG^UZ6!DT%@Q*KT.##=J:_^NJK]96O[LJ#3ZL063]:TY@/]-][DG*8_D+M)=5(X?'L]&_(@RZ4IOA@G&/?A&] M9ED.DH)T^4-;!_V41KV]+@)F!)\4M-L(VW6S!V7%=B]ANR8&F];*=IM6$A>N M2!@/"^/\+US.EX<-C\.P7SKJM[;M\()FPQ55>0[5\RO*6]WDIG@U*KY@9[R< ME$IWG:1\N53>>5Y4^O6%7K2*%Y?;UFK6'%J9%[-I '+B#&13 =BO,!5 &SMP MMOR=NM'M:_:]B?>9-<]C(CU@G0-).QG.7S$EX;5NJTYE'PAHS D/6$YCV?!8 MKB\ .1&&EU]#)^\;"#T]\HC3""E;J[;F9"L\U4-_?PYA]!$N8 MVR=&DA&^AN,3P7B?26X0E^ZM)&U!UR::COA$:1P('+/N>/B;YSFZ*9(=0AP1 M1KQ UYGGX! Q-(- =,"W M.,Z#]J"9%@<[QGOY_Q0 9?]L8I=3>#II,F4H.TNFV;R'#)EPKF/S5WB97\!" M@0YJA+#*0X$RI;E/B/O"/([(@=A.XEF!#>0AFV)&QKT FG[4[O$3#L2B619B MJ0YA.V,B1SZBLX?P-XCU'UZU\OFXHSX0_LJ3&$F%.W*G,((O8;(7L"IKO2+^ M6BE,"]".R2S8<0P=6@C/> 8CE"S5^SS XOV]%1&+IS"*8LA=0\#_\+V52$R. M+3:+H23PE6( %DMTLR0F,7DI)#&'29K%&Q:@-HC,YOK0J/^$8CZ><=Y0M(& M;Q,8,' FY^$O"9BYZ:PJSW= (<*='$+IZ)KK/N%P'S0K8!$J5[06'%T,97<6 MN7$,;(OH3G\%&LA6GP.I@.!@V X.O4Z.IJF/[::65HM![:=1M&;7D)]Z\2A! M 0F$G(S91?-%XE"^;(WO! MD?,>[/AF&OG-0.@[/) X)"4>K6D]*92X>.@FARSNJVZJE=P3^KU:GX*A$ZN' MFQ8:Y(WO[R6M)XN-C8-EVI_7^O2NB2;&88*G$.TXF!K'[1.=1/!%J8V-J'.A M$-G?0W#B5E)=8592S$DA1,C_281Q&1U/,RF8T<-\,:/]QI4!FCDAD\1#(P$V M#FL+1&F(?)$,8#/0"ES.NW%BWO??M/'D2U)>(3DP8=,C2)S8+:[I!-Y,]8,4 M%!]O%E0+'4>3Z# PA !9S1$P/;KC3E#G823L-:8TD!(A$'%KI_#-IF&&HN3- M1+@F3XZ89G!,2\HQB!#2,LTW<3\<*$@HH1:[C[ #.3^-'?L>UM[Q\4M.Z]G= MDN*#V?''8P(=,\7EB%/*^Z'\O '1($0EC!VSA\B0"=1*P9 FK^=@(\T1ZBO2 M]*;1(E<3TPD4W!SAO,SYIB;3=6QVX,-A'1Y=X@!M=^K=]+Y*Y _N!X&:)DI= MA'-"86M@S'02<,D';$V1+!%', >2$B>29CB3R K$O\/\U3/8#G N75N:O6O%DR+HH!-4 M1JXYNB!BFSZ1JU@X(1E#]%WXZPC8\L'DR(6I+["R&;",V"9K1QUZ';OTF6NW M1W/T 0$.FV!K(K\UIH\"KN4)PPI^8< IL 5BRXZ;LPE_#C1+H++:_,1^K[13 M7X(8="R.P 9RGHN-$,\VM$MG1<+[9G*L<>!=W%FN]D@X=IOEP-Z/"^NBK1 M/(6>E06]IL2QP^)#V7G-I0.NEB7>B0]7P!1VCF7REO@I@EHB=H"'(IRH&F?"_+;A $!VY>L(PB#1 M5+1D^_/>NZDR+-/6STS=F-SF$.DP;@_/#"6IV#!SV-3)M]GF\^C/?4IX />2 M@6U8)C\C-[8LMI9! U0K-,!70P/<,J=$9WT*6_J,PRQO"2:PJF(A216+J^3* M4Y]FG0"(?'G$-09 M=3[0F[@7(JE+FT+-C]9XQ\RD\] KQ!+D]C'HMOQWW9R@-R-D<4[+ 59QT-#R M_BS)S3KY!2@7DKLJ0VN];O/"T]83>3"UL%2!93F/'"S>M/_YT^?>$RLKH\< M-\#3RJJ# ?MI##J--G2U,?L4TJ\^\L?6_PG_,(U_=(=!S_O#_BFT:'EG^HV7 ML4&7Q.,(#7(;Z[98)AQI=J3!<;89N(YFX-QX[,:Q47_#4]W2GC#Q(.2=5!; M-.N0%.?,(/4G3.-_%M.+2/_X^%@W^<.ZP\EN1LW%OQV8-F@28[XQ/TD<9I^O M^5TZ]L'WHZ-KI#;_><-@BZ+O2A-NT_*4'C,]7BD+G746#WB#BP)BBHNN.:R0^K#"4!;(&I=>$5WT09 M6"RIYV7C[6QRZXM"N$CVCZG:9OM[LU4H\BI3I+-5T$DP6T$TKA"U1*UTX1J, MXA,H9RU1+R6N6!(%<5/\'G; W8F\-!8/2F4&&:O>(Q#[)GJ,0?[S"D-:JJY5 M2'9.=0QUA-EE/%J428< 2F%=EQJ&?SYB(6"?10E&H1XB# 19$<%+QO%25=$YO,X2,$8D@ MW+\*LW+]8!+]B:-W ]T745^1>[4H.,=^F7&X_X17T[+X..'?:3"P,!@GG-1@ M-\"$ ]MEL-O^1AP;!Y;JGL?J.: Q#[31, W%%@YAV)PP%)C'2&0.9!,2H\K* MP! 3$DS$^Y_N,0J(C9A>5/X&'D=Z8]9BTLF\R%P(,3,=;Z.Y.2N\*9RN")SB M,L*2 6'=L2BL M+3VBRQSYO8RT"JN,1^7K1.!AU@#G;X:RA+-Q*"_Y [P\6!0+Y 6B[.CH&FB> M.5,C+=0DW/ P0\%BI@M..B2J";6_EXB43X+YW/A+,OM=. \IE7>__8$S)+#\R<^ MP8C#"0]8NO#Y!)U??!X\?0I MWWPM$I$>NEKJVX4H6V\O:18+*WMY<7*4QQ*6C-0(7O$/>1;C3)@0FQ8BF#,6 MJ91P=F*61RBJD/7O/>[P?.(NG1&S)LG#<6Y7[CI$A;:2LU"(-KXK,-L+U&M1 M)8S7HX*A8E 2!R?VW@$6]SH(RUV*>)GI1=52D:%%T<^G5!\H3T7Y5%$;E#,0 MG\JCZ6$Q,.C,^Q,W&YZ<)D["%V$WGD7"=X@7#/X3YO3ZL1SFN3IUDG(6!IZH M7YE';1+5G!2X9%-4@H%RRHL"HR)('HGX=&%95$Q"N8TLS''#O'K:E!CQV:%6 M I1PYXX%4X^P="H?=ICH9"9%7*$CBH<7US0TG#WPF!_X0G'#Q-Z +X'+'XQ; MQ9R5>(NEYS3!N+:;KZ#BP';/.DDM.E8(U5'5Y)LFVE)*6_*VQ&J@=A5YE7F '7JUK$!DG8ER=='7 M]R;/$(!S(L7G,>/,8WA1]! 3.N%T"%S,#T]) I[0@&6ULL=#HC2G[)M86Q:C MG: BJ$/C(O(AE/7(4 $%#'>ZR_RG,%LD!/5+=1_*OAS^CP+KZ6P4%&4B41TT M )X)9H[A!'*S;T6Y;OB>R7/D,?_P<03_B][!E!&/'Y!1:D>A<&N%T);H]L."RU@?VQ 6(VB+ MJ+MA87#-U4=X$F/ES]!@2^I5QO(57X-=K8.AB)YU8>.BX...=F*XP3V/MJ&V M\!2FN#\PRYD(J35=&EUT2L:.P:SH,TM<&\JMJ#ZES<>:37[Q]:&C!]QD'*!A MQX<-M,3QB0?'?&Z8U"2>CZJBXAK%$Q"8L6C21_.=C+10Q*?F10EW6O.%_I4,%D@OJKZ"OA96PC5Y4O?8 M],.E"3.1>>MS:>]P18J7G4]Y,5"%Q/>BQ4 O3&CQ)Y7$)V!-VWCS*#0X3,Q6 M=DVQY#?<=CW%9< .O#0QXNJFSCT3*JP#ZI6)EZ$P ]J"LSJLV^MI(/[Q>+9EHYHD50R-% MBJ948#U*\*4BG6]H.8^ACA=ZE*;R8?/N[?"4Q">A*2=)B,!OR)?P6YC1J44I M))0(KUCLSQ6;-MR&8_P1^5YG>ITC[$1BRY24$4U&F98 M?(4NR_NP;W0GHCA%$1*EX*8H3_D*ID>'SA*3J[B".'2:B4%#QF 03E18<;:1 MTJ7%4)):VZF#+'3_A+P7W4H1:FR*01*#F6^O*(C<$N6'AUIGM:!DT;I M7.]T40,,;[%\!XUMPGO9VE2/0:TA1Z"7:D^6XU)R @K-,+EJ0JY0!63NNHEP MBO7MR2WH9N:#9J]G]A'UI1_X?,W_)ZUHKGN=#2]=B339QF'1JMR:.R$0V,N M].[YY=7=^1\@]R]/ZAOT;Z1Z/+FZO+VZ.#\]NCO#;08_?IQ=WMV2JV_DZOKL MYNCN'!YXA:'4SE$K ]4.="VN"F+"!_J(B3="LTMZH* M9\Q''\\!"N^L"*B.:@_FZ_P0^3IGF*^SXBC762KAE>'I5Z7FXM,B2H42XV@J M=",H];N[ ILO$/!*I0%VE38%<5[7Q9"K(=IW6\N!5H<5O:+M&K+V#@ ME2>UY#;)*TL ZZED5(>=$+^(HNB%(:XH-?JSO)0N\.9NL-!:)B:G9#H),S#B M%)(XL;PF$OM#@,/G$987E5?YZF+).+%6@W:ZF1()LHO&'/:[%4",$E.:MANK$EK&>8'>V[O54-,AGGU:3- M?L8OM+N2[(HG[&50L&6F?SEUK&:3MGNKFC 22;$I_U[>$3KG OL;X&1N:-\HTO75'\PH>P03X>XDML1U?^H*LG;KLFEYO5#(L.78K&R:3$VAO>R16E216<3/I:->NTN[ZMITZ75L MG1540*P)2$1R?@JZC4FJ#"H-E?:S^3(R2-V"VFV'*H7\/%)+7#S(8Q3 $ 3P MC4D)I4W[W4P*3&5POX2$*NWVY$OL6BD#)Z?2FIR"J=>A_6:1:(>D@K;7I*U" MF5M2"]I=YG7O!W&M$UJB,J8+@X>D2(=F@)C$UA>[TUUVBS7_ N0"6F M0X]69VWGW%:5X>S"J/4V+LUE5!-S=@'_^+ LPXT* [A#"R>7T949LE M.ZD*5=15KT]G8>U> M"\OJ=<#NVA78705VMP+8W?'1Q='ER1FY_?WL[.Y5(.Y.$:7-#>&M0ZB["F:N M %;76X"H>AT M1(0ZA8K@Z8HU:B@YBJHN3= FS4RY%K78=,DGP%I76EX+];^ MEYG%<\?P\GV^OGF80ZHCR2__5@X&&;U8)U@^V?;#J^.5?VI')R85EFD^R@]6 M)A(5%.$7!/A_T"PLDC0[\QW!^50;M*=FKA2](:!3I4?;2B;C=W>!3E.\>H.5 MYD71:.16B65'_C7G$DC%5B?#6I*)Q&*L=>=J!N-5XD#^#:RDNI8H31G6:^/Y MYEB+S+*<1ZQAS O>1578,']"U$)[WZ5J7^5-O.]0M=/C]>$FHO*A]23O\G9; MM-TK(ZB5TFC01G?50(=$LA"K;=F^X_("Q,"6\I*^6U:HO:Y"6X720^07A]=8 ML=U,0&Y3A ,#P*/I1TQ\M*_V:)**1FKB:;'5OFJR#V""+Y47KKV%=IJ MEU$+4MI=VE.WZC)>11)QAT<&R%MVZ0-;H]5>%?=:RIFUVK37VRJB]P;AG@2W M+66QE0N_V!^MK 8UH6I#4S+]'FH.0T$ M\=_8@H95\F4H[,8FTY'2V8AC7L!*6K')C=W1BV]8LT]%F78?&?0^^ M>\+LKTU3OA!\A]J3VJM8=$Z=?CDS"H&GW(#EIM"DI)>\>QR6IMV3E]U6\"*U M::^QF_7'YV1%/SC6 ^I<81[J4-.1NR1.,RUO?K32IHVL!5D*@?:-,;QW_^"8 M.H@UTR::\8 YT/(N1J=!.^U53Q@.8TT9W%]8.VZ3[KM,'X+*/JV6PV:&=.!@[:[B4+>>\ M6MMEI WF*9ZR(0,Y9O#"E%8Z-V#QD5DV_;O=I4IG8>959<(\9_!W:6-]E8"W M+XF7<@-,VS++B^JR+7Z[KX!X*@CN6&V@,,K1I$I3ON3?*F=QAQ26'<[H>7=X MF\I)_,WU_@J<+TMD)E:)8SLZL5=7C/,B1^E2,J#Y.O"02QXT*V 57^WHQ%Y' M?$TSDZA;<13X(\>%APS2;6$""?Z+ZA1I/HF [$E3H031L+E<@R]BX';2;(AO MOA!>TJ5#.\T.]RE!FSSS+*EVE&Y1S!^:%;_$;4,C[3[LD%Y_JIOP\4;J<7F9 MHD.;G7(Z%YJ=F371M8H*-).]J=!M]VBOE==MNHTN[ M*Z-!;ML*GT[)#<:!I2& K,&&IFY*'.*IM9IMJC:*A-8V7GYRA5DU6R S"OE& MMU.&")SG@"I@JS/?.!<<#8-^:L .IG1&513\7+:]SO..U )UM\ M._6%U-N6S2X\GY&5OKCHM+PB3>TU:*^Q:LQ:QIDU.PW:[)9(U5PDL"\+W6$M MG9SI]]<6CWES,KJS]O-MVPKTTF$LKY ;]HTQB-H%<[&QD7CGFZ%AL]VGW<[: M]IGDA]42R#>I #+?:J^T$W<>\*5"SMDIY)S-5^'^>A[W?+[Q8LI+%.CN5 6Z M-U&@.W]!DE&\2M%NT=V6*G??WL&/'V>7=[?DZALY.;K]G7R[N/K7J]3P/G_% MVMWI.J?'\0J_!KES^BI'Y?"E3SG^P4O*VG96+FM[-W(9(S_@X9%'SFR#&2N. M6(; M\?FMH5BP8_.=Q".:>'DM+X*Y(W5R:[T.[3L@GPI:EQ[!F>T3G&F\%_\P_D70>E2=62)E8VFJ4# MHQ2L=C:>6,X3V,:>[X!.C'E(S/8$YX4(E?*NBTH;K3(F6"I]JF2C#SLLT$Y& MFGW/40(QOS*^)2SS#738;U11BT@SF;,L%9 AO2(8I[+J=(*_KEWG 30PD%F( MF(4!*G\86*"8"?AF>1=$H8WNQNI[+>]I+>A>66TL^;K%-7>*R,=.\ '_8W,6#X2S#X->#7/,! M!/>#Q&Q<7A3U=H=VE9U'@A>1Y'>1<&]%BUE'5J:;>Y5=3^ M-\U5Q&A-3U2&E)A5ETIG++!MZ [P/3&R&_ M56K2&D:V1;[M[2@2YER319RWVHQ-;MH/P*R.^Y36"SV?30Z"B;R+H[9*>=^0 M=CJK:A?2"L7<>*[J&>[^Q&02=W>N9J!YJS.P8@=6>"V(7_H! M,V.Y2MG;%&\*[:\,*B_CQ!3:5G8.%SB/P<[#8U-J:[4&\RQT,5_FT%Z3-OLK MA"MEDE+7+D.8I[P2F1%4ONR2JDM[V1(V)1!4-86V"@5YY X@7TV7^1"S/7"& M!P'\D:^/25\)I(R9,35570'X2B89]]JEI5?137*@[$O 2RW:ZF^UW._FQ-FN MUYA&1*M6$8M?9@5-:=!^=P6M4R;IM7LU?VM=VNT7.1(E9BD% <96/>8E$F'/ M( JE8Z1<'RNBCI4-[Z:F9JM85X!<2Y:7H>W>1FJ,;EM,+P'+=;G,]:8WQ@]P M/K365W3VK>VF&A@)V=I_VP2XJZK,[) IML-Q%N'R]JH+]N68F$3:<#I,+(H= M"'O>,/W E=IZ[]%F(8^1Q*96K4T[665[UXSW3GA92F?,\,C0=<;$TRS&,YS_ M"LS)$OE96XW^KNJNDW)6O1(E-"\"TCY!JX/']M!GE,)->&/Z\IR,P0KM]T7> M#Q5+Q*ZM2*@DDKJ(_6[FJ*!OC1MZ5&EG0@:5_;[L7FJJ>?DCE04OH8U2VHEM MRX+_9MJ:K5<6?"DF)I$VG#:ZM">!.0:FEN7 =SYSQ_QZS,+I\@^J^S"R,FVM MV:7=UK8*UZW9-9#BTAQ0BHI5=YQ5NU1IE"EY9%Z'-I8)+Q=SE?2V M=(;?/&:;CDNX=L@E&,]S,IBE/2'ZB*L]BN\L1UOH--TF#W9Z)4O?E( !UROE MCAW7=1[A0\YWNF-[OAOH_/HS,E?95T+&F2E4*5,P:"ZSE43(-8N>L[+S8>ED MW73(F_UBKFYZ/.PM8(^=R3)!R&T&B+% M(CR38S%!;'&$_AP\D6%.H%!B2=>CS97M"2DGIO1I:^7[[:\APN6G915,EEK# M?'=X-APR78 0_](Y7!AQ-9\1/80.XP<\ M@AD!/^@IF\#YK%I"Y\T"Z$52,] MS^V,X;P#M*P$D]R""34DTP9S @%S:@83OWW$?-0=%$A-VFJ4$>6DIB@MVNBN M$ [<5E;>!?.\SYR#:(:/*.4/C)AE\ I >*E%YB6A[;+=CY+@ MY-O8319Q;659)M1\,F#WIFVCF0A:VX2YIK.XW'RY? 5@>O8W Z_P=DC8[M!^ MUN\O+40%[]*T#=@9G\E!HZZ@'R7K70D_+K 3U7J[P%YDB'P5[<*X9&_^J;+R MH3)WT"_F0OX>KV1GL6*EGU=M-HH\-6A/7;B3>;N;W,L[3\>62GOMA;NY&!VK M:S:5[;AM\;^,P1B6A\MXT9^JRS8[.K&M*^SO#F^993$W9"IFI&^5+YP<_V#3 M]Q4R)\I+F]G=JPJ+IY[KB=F-\/P;V>*EG9@,LBN83"Q>9%*S>'E?R\&JDY&% M0H:6\TA,&ZR/,2],5)V3.SJQ;:<+I3*#$@@6-&JC4KU2G@2]-2!T2S8EA3;; MI0,=[XC*+[HS9L37?C&/\]>K%$@HM @J55>N)R;9E)3.JO'TF*L^W1T=7YS! M[_M[7Z_3C8EVR)TYAA6^9(_DQAEK-A4?4'++7'/XA8PU]]Z$'O#1QG2G_PD\ MWQP^)?U>;[27N/W_.C@@WTQF&9_)M7;/OD C?P4,K(7/I$L.#J)5.CW_(QJ( M:/[ =R:?.?1TU&'LJ.G@9\^[>6$ U]/M\>&F9__U$_29T_W 9=J?!P,&$AK& M..%C3@^IDS,B@9#]LBY3A/F$E!'$V-%UUQF>94""X\/SRZN[\S\H.;\\J7_] M='RX^1YOSDZN+D_.+\Z/[LZO+LG5-_+]Z.B:W%V1RZO+ _[[ZPSD]NSB[.2. M'/^\/;\\N[TEMV???YQ=W@$IOEW=_."C>X6!U,YMXH^T'QF.84N;>+"M MH]^^D$?3\$>?2:_Q05CORXSWW7(JP*;-V),KG.OE/]YUWBUU[D24O!NYC(D6 M?\#S(T_\?F8;;%&LM* RM#9*O"306(P\BT^64Z:S\8"YI*G0(A'"G:2ANEX: MJ@6Q W=KBAEC8X/LL2Y[(\WI[5'(706DGMA'?1WAD=J,C-^R!V4$F M6!^^H^2]\AR)Y[^W/+6C-M1%C43A8H4VLBG2ZQS)+E"AJ=*>FD'=+CZ2K7M. MTI4F3>XPD7?SJ[39+0)1)+M0Z]!&:]5Y;2N$/LL]1/.(1CY@P,!W,(C@YHL^ M>:BOU(MDOGZ0=T+=>A%F^B"-0#HR#-YV%5O:T8EM1!853=M$TW3B,MWD\4J> M4*F-'1C-W]H2&1E;O?^1D[!< A93:;LE>\!I?3G"W,2^]377#R9+8I:6+&N< MMAMKJPGY)O/N^^T,+(VT.?=%=\@=UQ5MQQ:1"W//B$VLKM-G;*G3>9N*HGVJ6 MXWD2(Z34N@I5"P54)9[4RBYS60*I(?OLGH9<:_<*F2L?)5:2&_4B;"6/ 5:% M5'=\8E5(=3W^.;571I3/)FVM/"]90ZJHFHM"0('+JYXM$4/=IJ]N911H&6=U M4"[Q=9225JA98;5ZV\<:C9[/)B28R+L2:JN,^.E-L&U7O?\JKP"[\D?,Y<%M M.#0#%\48)?[(= TRT5S_27:9UNF6T>_0:JZ*KBN55)L3LO_N.,:C:5G$'$\T MT\64"H*&Y<*IERL!H-.AS6PQV"J'X@4DS.@ I\U" MM_FJ/14GPK3[&P$EEBZ+1%X]H$W;[3+B['=IIQ#(OE3B>;GV\%@TKK)T"4]P!K)UG<%.61 [_:6N6Y>@:%D@Y<=R) MPZM1?O]-&T^^9#!Z=@ELI*8J8,-EK(:7#27CE=HI"C3[M-O)1+P*46!;!D>: M/?59]MP]HZ.F=.M%[F[)G-Y5:Q7#S/A897B]@,I5AM?.!!,1LL !;<*9\!0) M]FO";$]BH:321JN,>3=JD_:;6X6&>GVPC*.D7 Y/+<2" />NR-5YBP :_6QJ M7Q5C>P']>K37D._N_W8!--YFP+I)&VHF8E'MI9=04*7=+,+!UC?3QB*-2V1* M;=44Z]%.JV1UNVM=V*5%7K!2RE9!4-=R4UUR];C? MH.UL^&S'U>-F$W3^%4 ;)#"TKG9=0^XV"^5R2JTA-_N%LCG7HB*O((RJN->. M3TS6Z,3.@APH3:JN7'M5QHEU"CJ&I(^RZLX8XZM:%6NM8JT5BD:%HK$CPFO5 M0/TV+YJ4$@8H-])=&@%6@;9(-JNM@[9L0A_3EB[4LTT5/Z^F3@DX*J?236G$ M5P4")..L*A"@-Y2]5($ 52! +]DVR^94OL&MU&O39JNJ2;923;(F[:DE2DQ^ M!EI#?BC\-LB/0AEB\LY):5"E#'45%G'5#L:/6RME(\HX)465#KHEGLYQ/*_C M0PDP6_H59LO6,%LVM.K'A^>75W?G?U!R?GE2?PT^.SZ\.3NYNCPYOS@_NCN_ MNB17WP@7DF='-Y?GE]]OR=T5N;RZY))S?R_Z]!6&5CNWB3]R D^S#3SR-]O9 M3UL+#%!8C$WW-,-(%?A/!?Y3@?^\&@TK\)\"4WP3X#_\T#MQ;#YMCK%BLWSG MYNO@WKR?U^W2D#>]3EX>RDZ _JQA\DW:RB;&[Q3>SU'*35C3/E:)J3LZL:V[ M/I)C1(2!^DC3%V^%R3DJEW5Z1? Y9KO3D\E65/B_7Q*1-GR_&7O-3YTE- MD7BW5^GS.Z=S+4QT)C558HZKDIUW0IQI5>9IE7FZ;M&5<^N'U)H2"ZOJYH_D M@NJG[3)XYF]F$(P5P\.@=^DCS;YGY%XS9=;L86N5T1_15'>^S%Q5AUI\LXIUYWJX?C>N57=8U,LEEM_1K99@58#0_% MCUR.F=[$"A9KKD0;,"1EPV9IH7 MX _;1Q;3'9L/;V Q8CL^ VYL2:S[E_'L;'=H5]FJVW5CXJVZT2CCK"2]T?@" M%IM*3\KANWFW&4FM_=80[:L;C=6-QN5W4Y2;Q QR=GQ^=WI$:@,Y=TPFD6P= M*UUKTU:O4%)DD82"$A$.;Y(52YC=H:/FN512<<5LPEP]5*Q?=&YGIS([Z>J30: M']X=/B,;H(5I&N$&-H=/*!12M Z;:]01S@EOBT\OQ=37>33_^NWJ\FZNRZFF M@4V"3V0:SAW9\XT=38/=Z#!AS;3%'6.731P7Y-/^7NAO]C 5@/@C!O]OO#WF?U@WCOD[*_ ])_V]ZXM#?O4G7N;Y\68F!9JVTSG[SR:_BC]EI9D MD]8WR]%RLO$"-0M:F7]1-.+<):XLQD+V>9Y5/TZOP4QCF^%-D_-D\J'O:@_,XN+4X;$8P?<&/.V;#\!A MT-@<7M2>26D&)@>.!M8_-IUK&--8HS'OPJ,WM^=U\H))JJE)OG2.J\[->V8R M%&="R?G%+257QSC%!KEW'?YJ8VM06S=%VJDWZ"INTNW"^@[8-[ =,1?,!Q/D#XQJ.8Z<>RF2%5&PH M 1NVY9%Q6J(DW^?$VL49SOD4'9DS6K<1*[ZO%ES_#2^D<* M0N^9&\=T?V^^Q4>?58CYF4_!8-22*UJX83)7:R@)GKD=@5.$45CST]KIU(AS MLY,IOV3Q*6XD+Z>4$FM!^F2! M3/]T?'7Z;\X_O]_]N#C\_U!+ 0(4 Q0 ( .F!358TSU'*-P, .\+ 1 M " 0 !B87-I+3(P,C,P,C$S+GAS9%!+ 0(4 Q0 ( M .F!35;W_8)W_PH &R' 5 " 68# !B87-I+3(P,C,P M,C$S7VQA8BYX;6Q02P$"% ,4 " #I@4U6476S[%$' "]6 %0 M @ &8#@ 8F%S:2TR,#(S,#(Q,U]P&UL4$L! A0#% @ MZ8%-5K+1K=HT$@ 7F@ !$ ( !'!8 '1M,C,V-34U9#%? M.&LN:'1M4$L! A0#% @ Z8%-5K<6H+#+/ ;>X" !4 M ( !?R@ '1M,C,V-34U9#%?97@Y.2TQ+FAT;5!+!08 !0 % $